• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
DXB 0.71% 34.8¢

DIMERIX LIMITED - Corporate Spotlight

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. It has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.More

No Corporate Spotlight currently available.

(20min delay)
Last
34.8¢
Change
-0.003(0.71%)
Mkt cap ! $191.0M
Open High Low Value Volume
35.5¢ 35.8¢ 34.5¢ $571.2K 1.621M

Buyers (Bids)

No. Vol. Price($)
15 160104 34.5¢
 

Sellers (Offers)

Price($) Vol. No.
35.0¢ 23957 2
View Market Depth
Last trade - 10.39am 07/05/2024 (20 minute delay) ?
Last
35.0¢
  Change
-0.003 ( 0.60 %)
Open High Low Volume
35.5¢ 35.5¢ 34.0¢ 583984
Last updated 11.05am 07/05/2024 ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.